Contineum Therapeutics(CTNM.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Contineum Therapeutics
CTNM.US
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications with high unmet need in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis, progressive multiple sclerosis, and chronic pain. It also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor which is in Phase 2 clinical trial to treat depression and relapse remitting MS; and CTX-343, a peripherally restricted LPA1R antagonist which is a brain penetrant drug candidate. The company was formerly known as Pipeline Therapeutics, Inc.
4.837 T
CTNM.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Contineum Therapeutics shares are trading lower after Morgan Stanley downgraded the stock from Overweight to Equal-Weight rating and lowered its price target from $23 to $14.

    benzinga_article·
    US
    CTNM
    -0.84%
    benzinga_article·
    US
    CTNM
    -0.84%

    Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Sale of Common Shares

    Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., reported the sale of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice. Contineum Therapeutics Inc. published the original content via EDGAR on January 06, 2026, and is responsible for the information.

    Reuters·
    US
    CTNM
    -0.84%
    Reuters·
    US
    CTNM
    -0.84%

    Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain Reports Disposal of Common Shares

    Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics Inc., has reported the disposal of common shares of the company. The full filing is available through the provided link. This news brief was generated by Public Technologies and is for informational purposes only, not to be considered as financial, investment, or legal advice.

    Reuters·
    US
    CTNM
    -0.84%
    Reuters·
    US
    CTNM
    -0.84%

    BUZZ-Contineum Therapeutics slides after upsized $90 million stock sale

    Contineum Therapeutics' shares fell 8.6% to $11.95 after announcing an upsized $90 million stock offering, increased from $75 million. The company sold approximately 7.35 million shares at $12.25 each, a 6.3% discount to the last close. Proceeds will fund the development of its experimental drug PIPE-791 and other R&D activities. The offering was managed by Goldman Sachs and others. All brokerages covering the stock rate it as a 'buy' or higher, with a median price target of $22. CTNM is down 10.8% year-to-date.

    Reuters·
    US
    GS
    -1.42%
    US
    CTNM
    -0.84%
    Reuters·
    US
    GS
    -1.42%
    US
    CTNM
    -0.84%

    Contineum Therapeutics shares are trading lower after the company announced the pricing of its $90 million million public offering of 7,346,938 shares at $12.25 per share.

    benzinga_article·
    US
    CTNM
    -0.84%
    benzinga_article·
    US
    CTNM
    -0.84%
    © 2026 Longbridge｜Disclaimer